A Phase 1 interventional study of Tuberculosis (TB) vaccine (Ad5-105K) and Placebo in Tuberculosis, sponsored by CanSino Biologics Inc.. Active, not recruiting at 1 site in Indonesia. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by CanSino Biologics Inc. · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Tuberculosis with a site in Indonesia — 8 open to participants now, 13 under way, 3 of them phase 3. Tuberculosis · Indonesia.
Among the 37 studies in Tuberculosis with a site in Indonesia, this one is the 27th largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2025, is one of 3 in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 28th registered.
1,171 studies on the registry are indexed under Tuberculosis; 176 are open to participants now.
Browse Tuberculosis studies →8 of the 37 studies in Tuberculosis with a site in Indonesia are open now. Recruiting first, the newest first:
PT Bio Farma · Sites in Indonesia
Ages 18–40 · Healthy volunteers
Universitas Padjadjaran · Sites in Indonesia
Ages 29 days+
National University Hospital, Singapore · Sites in Indonesia, Malaysia, Singapore
Ages 21+
Johns Hopkins University · Sites in Indonesia, India, Mozambique and 4 more countries
Ages 0 days–9 yrs
Universitas Padjadjaran · Sites in Indonesia
Ages 18–55 · Women only
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 49 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 8 · Phase 4 1
First in 2006; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 150 across 821 interventional studies indexed under Tuberculosis.
Median enrollment 92 across the 34 interventional studies, 50 across the 3 observational. Of the 22 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 37 have an industry lead sponsor. The 10 most frequent:
CanSino Biologics Inc. is the lead sponsor of 41 studies on the registry; 6 are open to participants now.
CanSino Biologics Inc. has 1 study filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Tuberculosis with a site in Indonesia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253715Phase 3Johns Hopkins UniversityShortened Regimen for Drug-susceptible TB in Children | 2027-09-30 |
| NCT07703696Universitas DiponegoroEffectiveness of Psychosocial Counseling in Patients With a New Tuberculosis Diagnosis | 2026-11-30 |
| NCT07126041Oxford University Clinical Research Unit IndonesiaScalable Public Health Empowerment, Research, and Education Sites (SPHERES) | 2026-12-31 |
| NCT07293455Universitas PadjadjaranEvaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia | 2027-03-31 |
| NCT07647107PT Bio FarmaA Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 37 studies in Tuberculosis with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant's gender and age should be balanced in each group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 doses of Ad5-105K vaccine (0.1ml) on Day 0
Biological: Tuberculosis (TB) vaccine (Ad5-105K)
1 doses of placebo (0.1ml) on Day 0
Biological: Placebo
1 doses of Ad5-105K vaccine (0.2ml) on Day 0
Biological: Ad5-105K
1 doses of placebo (0.2ml) on Day 0
Biological: Placebo
1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth
1 doses of placebo on Day 0, IH
1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH
1 doses of placebo on Day 0, IH
Occurrence of solicited adverse events (AEs)
Time frame: Within 7 days after vaccination
Occurrence of solicited AEs
Time frame: Within 30 mins after vaccination
Occurrence of unsolicited AEs
Time frame: Within 28 days after vaccination
Occurrence of serious adverse events (SAEs) and adverse events of special interest (AESI)
Time frame: Through study completion, an average of 6 months
Occurrence of abnormal hematology and chemistry laboratory assessments
Time frame: On Day 3 after vaccination
Geometric mean titer (GMT) of anti-TB75K and anti-Ag85A IgG antibodies before vaccination
Time frame: On Day 14 and Day 28 post-vaccination
Expression level of IFN-γ, TNF-α, IL-2, and IL-17 in 105K specific CD4+/CD8+ T cells evaluated by ICS
Time frame: Before vaccination and on Day 14 and Day 28 post-vaccination
Started Nov 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.
Of 60 phase 1 interventional studies under Tuberculosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 25. This study's planned 9 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.